Nicole Daley

Ms. Daley’s recent client representations include the following:

IPOs and Capital Markets Transactions

• Karuna Therapeutics in its $100 million initial public offering.
• BioDelivery Sciences International in its $60 million follow-on public offering.
• Alnylam Pharmaceuticals in a $387.5 million follow-on public offering.
• A biotechnology company in its corporate reorganization and $170 million Regulation S offering.*

Private Financings

• Beta Bionics in its $63 million Series B2 financing.
• Karuna Therapeutics in its $82 million Series B financing.
• Thrive Earlier Detection Corp. in its $110 million Series A financing.

Joint Ventures, M&A and Collaborations

• BlueRock Therapeutics on its agreement to be fully acquired by Bayer AG for up to $1 billion.
• Ultragenyx Pharmaceutical Inc. on its partnership with GeneTx Biotherapeutics LLC to develop GeneTx’s GTX-102.
• Arvinas, Inc. in its collaboration with Bayer to jointly launch a new company to leverage Arvinas’ PROTAC technology for agricultural applications.
• Alnylam Pharmaceuticals in a $400 million equity financing closed in connection with Alnylam’s collaboration with Regeneron Pharmaceuticals.
• An IP commercialization company in its acquisition of assets and strategic collaborations.*
• A vertically-integrated real estate company in a $300 million joint venture.*
• A global provider of digital communication services, in its $640 million going-private transaction.*
• A public business software company in its $600 million stock-for-stock acquisition by another global public company in the electronic business solutions industry.*
• A global provider of telecom products and services, in its $272 million sale of assets involving operations and employees in over 20 countries.*

*Denotes experience prior to joining Goodwin